FRAX fracture risk in rheumatoid arthritis patients 65 and older
Official title: Appraising the Fracture Risk Assessment Tool (FRAX) in persons with rheumatoid arthritis
Funded at Augusta University · NIH-11404833 · Data updated 2026-11-12
This grant tests how well the FRAX fracture risk tool predicts fractures in people with rheumatoid arthritis who are 65 and older.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project start | September 1, 2025 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $177,120 |
| NIH project number | 5K08AR083508-02 |
| Project ID | NIH-11404833 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 65 and older with rheumatoid arthritis who are Medicare beneficiaries and evaluated for fracture risk.
✕Less likely to help
Patients outside the 65+ RA population or without access to Medicare data may not benefit from the findings.
What this research studies
If you have rheumatoid arthritis and are 65 or older, this project looks at how accurately FRAX predicts future fractures in real-world, diverse patients. Researchers will compare FRAX predictions with actual fracture outcomes over time and see how it performs against the general population. The study will use Medicare-based data to analyze risk factors and determine if adjustments are needed for RA patients. The goal is to improve which patients get preventive treatment to reduce serious fractures.
Why it matters
Potential benefit: Better, more accurate fracture risk answers could lead to targeted prevention and treatment for RA patients, potentially lowering fracture rates.
How similar studies have gone: Prior studies show FRAX performance varies by population; this study will clarify applicability in contemporary, diverse RA patients.
Where this research is happening
-
Augusta University
Augusta, United States Active
Researchers
- Principal investigator: Elam, Rachel Elizabeth — Augusta University
- Study coordinator: Elam, Rachel Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.